CLINICAL SIGNS AND DIAGNOSIS OF ADENOVIRUS CONJUNCTIVITIS

PhD, Yangieva Nodira Rakhimovna, Head of the Department of Ophthalmology,
PhD, Kuryazova Zebiniso Hushnudovna, Associate of the Ophthalmology,
Tashkent State Dental Institute, Uzbekistan

DOI: https://doi.org/10.31435/rsglobal_sr/31052019/6492

ABSTRACT
The features of the clinic and treatment of patients with adenoviral keratoconjunctivitis were studied on the example of 112 patients aged 19-57 years

KEYWORDS
Adenovirus infection, PRS rapid test, antiviral treatment

Citation: Yangieva Nodira Rakhimovna, Kuryazova Zebiniso Hushnudovna. (2019) Clinical Signs and Diagnosis of Adenovirus Conjunctivitis. Science Review. 4(21). doi: 10.31435/rsglobal_sr/31052019/6492

Copyright: © 2019 Yangieva Nodira Rakhimovna, Kuryazova Zebiniso Hushnudovna. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Adenovirus infection is an acute respiratory disease in which there is intoxication syndrome, inflammation of the cervical lymph nodes, pathological processes of the upper respiratory tract (URT), follicular conjunctivitis. It is characterized by epidemic outbreaks, which can lead to significant economic losses, including due to temporary disability of patients, and in some cases cause a persistent decrease in visual acuity. The search for simple methods of treating this disease which are available for use in primary ophthalmological services, the use of rapid methods for diagnosing adenoviral conjunctivitis at the earliest stages of the development of the disease and preventing possible complications remains relevant.

The goal is to study the clinical features and treatment of patients with adenoviral keratoconjunctivitis.

Material and methods. The study included 112 patients aged 19-57 years old with adenoviral keratoconjunctivitis (AVKC) who received treatment in the eye department of the 3rd clinic of the Tashkent Medical Academy. Men and women among the patients we observed were noted in almost the same percentage of observations.

Depending on the nature of the therapeutic measures, the following groups of patients were identified: the first (main) - 50 patients, virgan (ganciclovir) was used in the treatment at the background of traditionally used medical products (prescribing immunocorrective, anti-inflammatory, desensitizing medical products for general and local use); the second (control) - 62 persons, only traditionally used drugs were used in the treatment. Patients in both groups were comparable in gender, age and nature of the clinical developments of the disease.

Existing tests are based on the detection of antigens, nucleic acids, electron microscopy and virus isolation in cell culture. The last 2 tests are performed in special laboratories. Commercially available rapid tests to detect adenoviral antigen are less sensitive and specific than nucleic acid tests, but they can be easily and quickly applied in clinical practice. Such tests, according to the results of various studies, have a sensitivity of from 9 to 88% and specificity from 91 to 100% [26, 27].
Detection of nucleic acids using amplification methods such as PCR is a diagnostic test of choice for EKK due to its high sensitivity, specificity and speed of execution [2, 8].

For the diagnosis of adenoviral ophthalmoinfection, we carried out an immunochromatographic rapid test, PRS Adeno Detector, manufactured in the USA. Testing was conducted in the office of an ophthalmologist clinician. Using a collector, a tear was taken from the lower arch and placed in a plastic cassette. The absorbent part of the cassette was immersed in the buffer for 15 seconds, then the exposure time was 10 minutes. If there is an adenovirus antigen in the test material, two red bands appear in a special cassette window - first the analysis band, then the control band.

In patients of the first group, 0.15% ganciclovir eye gel under the commercial name Virgan (Santen, Finland) was used, which is a synthetic nucleoside analogue of 2-deoxyguanosine. Virgan was administered in the form of instillations, one drop in 4-5 times a day. This drug was used in the treatment of patients in the main group from the first day of their stay in hospital for 10-21 days.

The criteria for the efficiency of treatment were the terms of clinical recovery of this category of patients, including the disappearance of discharge from the conjunctival cavity, normalization of the conjunctiva, resorption, or replacement of active, slightly epithelial and subepithelial infiltrates with flat opacities, increased visual acuity, reduced due to the disease.

**Results.** Patients were admitted to the department in terms of four days to two weeks from the starting of the disease. In one third of cases, patients received treatment courses, and sometimes with unreasonable massive prescription of hormonal and antibacterial drugs, which caused the severity of the clinical picture of the disease, the development of toxic-allergic reactions and extended the time for further treatment.

The results of diagnostics using the PRS Adeno Detector immunochromatographic method showed the following results: Considering the early period of treatment of patients with acute conjunctivitis, the adenovirus antigen was detected in 103 patients from the studied patients, i.e. at 92% of patients. The diagnosis and treatment of patients was based mainly on data from clinical studies.

Upon admission, patients complained of an increasingly pronounced foreign body sensation in one eye (right or left, depending on the side of the leading hand), which can start from the nasal angle of the eye and move to the lateral one during the illness. Later the patient complained on the appearance of swelling of the eyelids, tearing, itching, photophobia and blurred vision. In 74% of patients, lighter manifestations usually occurred on the other eye in 2–7 days.

In the acute period of the disease, the general clinical symptoms: an increase in body temperature, headache, malaise, and signs of lesions of the upper respiratory tract were observed, respectively, in 84.0% and 86.67% of the patients of the main and control groups.

All patients had eyelid edema, half of them had a strongly pronounced. These changes were accompanied by conjunctival edema. In patients of the main and control groups, there was a hyperemia of the mucous membrane of the eyelids and the eyeball, and, respectively, in 84.0% and 90.0% of cases it was strongly pronounced.

Hemorrhagic manifestations of the disease were observed in 88.0% of patients of the first and 83.33% of patients of the second group. It should be noted that point hemorrhages were most frequently diagnosed (72.0% and 70.0%). Extensive hemorrhages were observed much less frequently (16.0% and 16.7%). Hemorrhages were localized mainly in the upper eyelid and transitional folds.

Mucous follicle disease was observed in 79.0% of the patients of the main and 82% of the control group, which was localized in almost 2/3 of the observations in the area of the transitional fold, and in the remaining cases, small superficial follicles were observed on the entire mucosal surface of the eyelids.

Conical changes appeared on the 5th-12th day of the disease. Corneal lesion was revealed by the development of edema and infiltrates against the background of a decrease in its sensitivity. Epithelial infiltrates (main group - 24.0%, control group - 23.3%) were small, they were located randomly over the entire surface of the cornea. Moreover, more often they initially observed their appearance on the periphery of the cornea. In the future, in some cases, a gradual increase in the number of infiltrates was noted with their location in the optical part, which led to a decrease in the patient's visual acuity. Mixed (epithelial-subepithelial) infiltrates in the form of confluent coin-like infiltrates were observed less frequently - in 28.0% and 33.3% of patients in the main and control groups. Subepithelial infiltrates were recorded in 44.0% and 43.3% of cases. In 8 of 24 patients of the first group and in 4 of 16 from the second group, signs of the development of iris edema and the formation of posterior synechias were noted against the background of a deep corneal lesion.

Analysis of the clinical picture of eye lesions in patients with AVKC showed that there were no statistically significant differences in the nature of the ophthalmoscope status in the main and control groups.
Clinical observations have shown that when using the medical product Virgan in the complex treatment of patients with AVKC, against the background of traditionally used drugs, a positive effect was observed already in the first days of treatment. Patients of the main group on average 2-4 days earlier noted a decrease in complaints of lacrimation, photophobia, and foreign body sensation in the eye than patients in the control group.

In the first group of patients, the disappearance of discharge from the conjunctival cavity, normalization of the conjunctiva was observed in 4-5 days earlier than in the second group.

In patients of the first group, the initial signs of epithelialization of the cornea in the presence of epithelial and mixed infiltrates were noted on 2-3 days of treatment, and the periods of complete epithelialization ranged from 3 to 10 days, the average period of corneal edema resorption was 5-7 days. In the control group, corneal edema, respectively, disappeared for 6-8 days, the beginning of corneal epithelialization was noted at a later date from the start of treatment (4-6 days), and its complete epithelialization was noted for 10-12 days. Resorption, or the replacement of active, slightly reproducing epithelial and subepithelial infiltrates by flat opacities in the main group of patients in whom virgan was prescribed in complex treatment, proceeded 4-6 days faster than in the group of persons for whom this drug was not used.

The duration of treatment in the main group ranged from 12 to 16 days. The duration of treatment for individuals who did not receive Virgan ranged from 15 to 20 days.

In the course of treatment, an increase in visual acuity was observed in 92.0% of the main group and 83.3% of the control group. The reason for the decrease in visual acuity in patients of both groups was corneal opacities in the area of inflammatory foci located in its optical zone.

In order to prevent post-infection dry eye syndrome (DES) arising due to the loss of goblet cells, all patients were tested Schirmer. In 17 patients of the main group and 22 patients in the control group of 2/3 of the patients, discontinuity of the tear film and a feeling of impurity in the eye were found. Patients were prescribed artificial tears.

Conclusions.

1. Conducted researches allowed clarifying the features of eye damage caused by adenoviral infection.

2. The use of the medical product Virgan in the complex treatment of patients with AVKC helps to reduce the clinical severity of corneal damage (shortening the corneal epithelization time, resorbing corneal infiltrates), reducing the treatment time for patients by 5-6 days.

3. For the prevention of dry eye syndrome in patients undergoing adenovirus infection, it is advisable to carry out the Schirmer test.